Navigation Links
Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Date:5/14/2009

LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.

Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data, 2007 sales of Enlon(R) and Enlon-Plus(R) totaled $2,727,000 and 307,000 units.

Bioniche will supply Enlon(R) in 10 mg/mL, 15 mL vials and Enlon-Plus(R) in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus(R).

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... Last ... planning for corporate executives and entrepreneurs, held The Future of San Diego Life Science ... the San Diego life science community attended the event with speakers Dr. Rich Heyman, ...
(Date:5/23/2016)... Oxitec CEO Hadyn Parry ... a.m. ET before the United States House Committee on Science, ... play in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec ... gene. Trials in Brazil , ...
(Date:5/20/2016)... ... ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ., is proud ... of their own patients with the VetStem Cell Therapy. Each of these veterinarians has ... patients. , The veterinarians are Dr Ross Rich former owner of Cave Creek ...
(Date:5/19/2016)... Columbia , May 19, 2016  AdvancedFlow ... Innovations Inc. (AGI), based out of ... Greenlane Biogas Ltd. to its existing portfolio of ... manufacturing agreement. AFS along with its sister companies ... is a vertically integrated industrial group that specializes ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):